Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.
暂无分享,去创建一个
Rebecca L Morgan | Bryce D Smith | Yngve Falck-Ytter | Amy Jewett | M. Alter | D. Holtzman | J. Ward | Y. Falck‐Ytter | D. Rein | N. Patel | Bryce D. Smith | A. Jewett | R. Morgan | C. Teo | Deborah Holtzman | David B. Rein | Chong-Gee Teo | David B Rein | John W Ward | Miriam Alter | Anthony K. Yartel | Nita Patel | Geoff A Beckett | Brittney Baack | Anthony Yartel | Brittney N. Baack | G. Beckett | Y. Falck-Ytter | Amy Jewett
[1] K. Migita,et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus , 2010, Journal of Gastroenterology.
[2] H. Margolis,et al. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .
[3] Yasuyuki Arakawa,et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.
[4] G. Guyatt,et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.
[5] R. D. Bruce,et al. Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users , 2006, Journal of acquired immune deficiency syndromes.
[6] Angelique Zeringue,et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. , 2011, Gastroenterology.
[7] Rachel S Tocco,et al. Public health impact of antiviral therapy for hepatitis C in the United States , 2009, Hepatology.
[8] T. Therneau,et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] G. Everson,et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.
[10] E L Murphy,et al. Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.
[11] A. Outlaw,et al. Characteristics Associated With Retention Among African American and Latino Adolescent HIV-Positive Men: Results From the Outreach, Care, and Prevention to Engage HIV-Seropositive Young MSM of Color Special Project of National Significance Initiative , 2010, Journal of acquired immune deficiency syndromes.
[12] T. Nakajima,et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.
[13] S. Sonnad,et al. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey , 2001, Journal of viral hepatitis.
[14] C. Cunningham,et al. Medical and Support Service Utilization in a Medical Program Targeting Marginalized HIV-infected Individuals , 2008, Journal of health care for the poor and underserved.
[15] T. Asselah,et al. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[16] P. Patel,et al. Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008. , 2009, MMWR. Morbidity and mortality weekly report.
[17] D. Sinn,et al. Disease progression and the risk factor analysis for chronic hepatitis C , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[18] Gordon H Guyatt,et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.
[19] Gordon H Guyatt,et al. GRADE guidelines: 9. Rating up the quality of evidence. , 2011, Journal of clinical epidemiology.
[20] H. Thomas,et al. Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications , 2007, Journal of viral hepatitis.
[21] Michael J. O'Grady,et al. Economic model of a birth cohort screening program for hepatitis C virus , 2012, Hepatology.
[22] Gerald Gartlehner,et al. [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[23] A. Sanyal. The Institute of Medicine report on viral hepatitis: A call to action , 2010, Hepatology.
[24] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[25] B. Graubard,et al. Data and trends in cancer screening in the United States , 2010, Cancer.
[26] D. Rein,et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[27] M. Alter,et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.
[28] W P Havens,et al. Viral hepatitis. , 1970, The Medical clinics of North America.
[29] R. Hays,et al. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment , 2005, Hepatology.
[30] P. Belperio,et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[31] Shimul A. Shah,et al. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? , 2011, Expert review of gastroenterology & hepatology.
[32] T. Poynard. [Hepatitis C: natural history, biology, treatment monitoring]. , 1999, Pathologie-biologie.
[33] Stuart Berman,et al. Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[34] N. Enomoto,et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection , 2010, Hepatology.
[35] Hirokazu Takahashi,et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011, Journal of gastroenterology.
[36] G. Guyatt,et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.
[37] S. Holmberg,et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care , 2005, AIDS.
[38] G. Foster,et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing , 2010, Transfusion.
[39] Sheng-Nan Lu,et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy , 2011, International journal of cancer.
[40] R. Chou,et al. Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force , 2004, Annals of Internal Medicine.
[41] J. Fleishman,et al. Effect of Case Management on Unmet Needs and Utilization of Medical Care and Medications among HIV-Infected Persons , 2001, Annals of Internal Medicine.
[42] G. Norkrans,et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection , 2002, Journal of viral hepatitis.
[43] Y. Imai,et al. Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.
[44] M. Ghany,et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.
[45] Gordon H Guyatt,et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.
[46] Mark E. Johnson,et al. HIV Risk Behavior Self-Report Reliability at Different Recall Periods , 2009, AIDS and Behavior.
[47] H J Alter,et al. Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.
[48] K. Mayer. Introduction: Linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] J. Tulsky,et al. The medical management of opioid dependence in HIV primary care settings , 2006, Current HIV/AIDS reports.
[50] Hirokazu TakahashiToshihiko,et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011 .
[51] R. Garfein,et al. Self-Reported Hepatitis C Virus Antibody Status and Risk Behavior in Young Injectors , 2006, Public health reports.
[52] M. Dembert,et al. Principles and practices of screening for disease. , 1988, Military medicine.
[53] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[54] R. Merion,et al. Liver and Intestine Transplantation in the United States, 1997–2006 , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[55] K. Holmes,et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] Peter J. Richardson,et al. Antiviral Treatment for Hepatitis C Virus is Associated With a Reduced Risk of Hepatocellular Carcinoma in a National Cohort of U.S. Veterans , 2011 .
[57] E. Schiff,et al. Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[58] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[59] S. Sonnad,et al. Current practice patterns of primary care physicians in the management of patients with hepatitis C , 1999, Hepatology.
[60] G. Guyatt,et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.
[61] B. Bacon,et al. Chronic hepatitis C: an age wave of disease burden. , 2005, The American journal of managed care.
[62] G. Guyatt,et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.
[63] H. Margolis,et al. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.
[64] E. Schiff,et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.
[65] F. Altice,et al. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] E. Parise,et al. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis. , 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[67] R. Garfein,et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. , 2011, The Journal of infectious diseases.
[68] V. Miller,et al. Buprenorphine and HIV primary care: new opportunities for integrated treatment. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] M. Alter,et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. , 2011, Archives of internal medicine.
[70] H. Marusawa,et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study , 2012, Journal of Gastroenterology.
[71] USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[72] M. Golden,et al. Patient acceptance of universal screening for hepatitis C virus infection , 2011, BMC infectious diseases.
[73] Inda,et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.
[74] G. Guyatt,et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.
[75] Z. Younossi,et al. Screening for hepatitis B, C and non‐alcoholic fatty liver disease: a survey of community‐based physicians , 2009, Alimentary pharmacology & therapeutics.
[76] Sanjeev Arora,et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. , 2011, The New England journal of medicine.
[77] F. Molitor,et al. Locating and linking to medical care HIV-positive persons without a history of care: Findings from the California Bridge Project , 2006, AIDS care.
[78] Gerald Gartlehner,et al. [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[79] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[80] A. Clouston,et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis , 1999, Hepatology.
[81] M. Alter,et al. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[82] Yoshiyuki Suzuki,et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. , 2010, The American journal of medicine.
[83] Jean-Michel Pawlotsky,et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.
[84] H. El‐Serag. Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[85] ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. , 2007, Obstetrics and gynecology.
[86] J. Ferrante,et al. Family physicians' knowledge and screening of chronic hepatitis and liver cancer. , 2008, Family medicine.
[87] L. Rodrigo,et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis , 2003, Hepatology.
[88] C. Christiansen,et al. Hepatitis C testing practices and prevalence in a high‐risk urban ambulatory care setting , 2011, Journal of viral hepatitis.
[89] R. D. Bruce,et al. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users , 2010, AIDS.